Literature DB >> 17415562

Imaging of pseudoneoplastic masses associated with allografts.

Taj M Kattapuram1, Deepak K Ozhathil, Francis J Hornicek, Mark C Gebhardt, Henry J Mankin, Andrew E Rosenberg, Susan V Kattapuram.   

Abstract

OBJECTIVE: The objective of this study is to describe the imaging features of non-neoplastic masses suspected of being tumor recurrences adjacent to allografts. The allografts were utilized for the treatment of various musculoskeletal tumors.
MATERIALS AND METHODS: We reviewed the medical records and imaging studies of 56 patients who were suspected of having recurrent tumors following surgical resection and allograft replacement treatment for a variety of musculoskeletal neoplasms. The imaging modalities included radiographs, CT, and MRI.
RESULTS: There were 47 cases of recurrent tumors. All tumor recurrences were in the soft tissues of the surgical bed (41 patients), or in the native bone adjacent to the host/allograft junction (6 patients). None of the recurrences originated in the allografts. Nine patients suspected of having recurrences were discovered to have non-neoplastic masses. Five of these were very closely related to the allograft, wrapping around parts of the allograft, and the other 4 were in the surgical bed, 2 of which were abscesses and two were seromas.
CONCLUSION: Most masses arising in the vicinity of allografts implanted following resection of musculoskeletal tumors represent recurrent neoplasms. A minority are reactive processes or abscesses or fluid collections. These "pseudoneoplasms," specifically those closely related to the allografts, have specific imaging characteristics that help distinguish them from recurrent tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415562     DOI: 10.1007/s00256-007-0292-8

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  20 in total

1.  Treatment of giant cell tumors with allograft transplants: a 30-year study.

Authors:  Henry J Mankin; Francis J Hornicek
Journal:  Clin Orthop Relat Res       Date:  2005-10       Impact factor: 4.176

2.  Allograft fractures revisited.

Authors:  J I Sorger; F J Hornicek; M Zavatta; J P Menzner; M C Gebhardt; W W Tomford; H J Mankin
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

3.  Infection in massive bone allografts.

Authors:  Henry J Mankin; Francis J Hornicek; Kevin A Raskin
Journal:  Clin Orthop Relat Res       Date:  2005-03       Impact factor: 4.176

4.  Magnetic resonance imaging features of allografts.

Authors:  S V Kattapuram; M S Rosol; D I Rosenthal; W E Palmer; H J Mankin
Journal:  Skeletal Radiol       Date:  1999-07       Impact factor: 2.199

5.  A computerized system for orthopaedic oncology.

Authors:  Henry J Mankin
Journal:  Clin Orthop Relat Res       Date:  2002-05       Impact factor: 4.176

6.  Non-neoplastic causes of high signal intensity at T2-weighted MR imaging after treatment for musculoskeletal neoplasm.

Authors:  D M Panicek; L H Schwartz; R T Heelan; J F Caravelli
Journal:  Skeletal Radiol       Date:  1995-04       Impact factor: 2.199

7.  The use of frozen cadaveric allografts in the management of patients with bone tumors of the extremities.

Authors:  H J Mankin; M C Gebhardt; W W Tomford
Journal:  Orthop Clin North Am       Date:  1987-04       Impact factor: 2.472

8.  MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations.

Authors:  D Vanel; L G Shapeero; T De Baere; R Gilles; A Tardivon; J Genin; J M Guinebretière
Journal:  Radiology       Date:  1994-01       Impact factor: 11.105

9.  Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy.

Authors:  D Vanel; M J Lacombe; D Couanet; C Kalifa; M Spielmann; J Genin
Journal:  Radiology       Date:  1987-07       Impact factor: 11.105

10.  Intercalary bone allografts: radiographic evaluation.

Authors:  S V Kattapuram; W C Phillips; H J Mankin
Journal:  Radiology       Date:  1989-01       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.